| Literature DB >> 30205005 |
Timothy R Hodges, Jason R Abbott, Andrew J Little, Dhruba Sarkar, James M Salovich, Jennifer E Howes, Denis T Akan, Jiqing Sai, Allison L Arnold, Carrie Browning, Michael C Burns, Tammy Sobolik, Qi Sun, Yugandhar Beesetty, Jesse A Coker, Dirk Scharn1, Heinz Stadtmueller1, Olivia W Rossanese, Jason Phan, Alex G Waterson2, Darryl B McConnell1, Stephen W Fesik2.
Abstract
Son of sevenless homologue 1 (SOS1) is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS. In its active form, GTP-bound RAS is responsible for numerous critical cellular processes. Aberrant RAS activity is involved in ∼30% of all human cancers; hence, SOS1 is an attractive therapeutic target for its role in modulating RAS activation. Here, we describe a new series of benzimidazole-derived SOS1 agonists. Using structure-guided design, we discovered small molecules that increase nucleotide exchange on RAS in vitro at submicromolar concentrations, bind to SOS1 with low double-digit nanomolar affinity, rapidly enhance cellular RAS-GTP levels, and invoke biphasic signaling changes in phosphorylation of ERK 1/2. These compounds represent the most potent series of SOS1 agonists reported to date.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30205005 PMCID: PMC8314423 DOI: 10.1021/acs.jmedchem.8b01108
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446